Dr. Tallarico is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1001 Calumet Ave
Dyer, IN 46311Phone+1 219-924-8178Fax+1 219-924-8179
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2014 - 2017
Loyola University Medical CenterResidency, Internal Medicine, 2010 - 2013
University of Illinois College of MedicineClass of 2010
Certifications & Licensure
IN State Medical License 2017 - 2025
IL State Medical License 2010 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 54 citationsPredictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.Narendranath Epperla, Mehdi Hamadani, Amanda F. Cashen, Kwang Woo Ahn, Eunhye Oak
Hematological Oncology. 2017-01-08 - 7 citationsPembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.James Godfrey, Hongtao Liu, Jovian Yu, Michael Tallarico, Emily Curran
Blood Advances. 2023-03-28 - 20 citationsMature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents.Vinodh Pillai, Michael Tallarico, Michael R. Bishop, Megan S. Lim
British Journal of Haematology. 2016-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
